News

Pfizer (NYSE: PFE) and Roche (OTC: RHHBY) have disappointed investors this year. Pfizer's shares have dropped more than 39% this year, and it's trading near its 52-week low. Roche has seen its stock

Pfizer (NYSE: PFE) last year brought in record sales of more than $100 billion thanks to its dominance in the coronavirus prevention and treatment markets. The company sells the top vaccine

Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) have been in agreement on a lot since the beginning of the pandemic. They both recognized the importance of eventually launching combined vaccines --

Pharmaceutical giant Pfizer (NYSE: PFE) wasn't looking very tall or strong on the stock exchange Tuesday. The company's share price dipped by nearly 2% over the course of the trading session

This vaccination season could be a key moment for vaccine makers and investors. That's because it's offering us a first glimpse into the future coronavirus vaccine revenue opportunity. Companies

If you're looking for income-generating investments to fuel your retirement dreams, it's hard to go wrong with dividend-paying stocks in the healthcare sector. After all, people need medical care

Pfizer (NYSE: PFE) and Gilead Sciences (NASDAQ: GILD) are two of the world's largest and most prominent drugmakers, not that this has somehow prevented investors from selling off their shares this

Shares of UnitedHealth Group (NYSE: UNH) climbed as much as 3.6% early Friday, then settled to trade up around 2.3% as of 2:30 p.m. ET after the the healthcare benefits company announced strong

Image source: The Motley Fool.

UnitedHealth Group (NYSE: UNH)Q3 2023 Earnings CallOct 13, 2023, 8:45 a.m. ET

Operator

Continue reading

Source Fool.com

Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) are two top pharmaceutical companies that are pursuing growth opportunities. Pfizer is looking to build up and diversify its business as its COVID

UnitedHealth Group (NYSE: UNH) is one of the largest healthcare companies in the world. It's already a top health insurer in the U.S., but that doesn't mean the company isn't working to be even

High-yield dividend stocks are a powerful way to boost a portfolio's annual performance. By reinvesting the dividend and regularly buying more shares, these stocks can produce impressive returns

Pfizer (NYSE: PFE) sells a wide variety of medicines across treatment areas such as autoimmune diseases and oncology. But it probably is most known for its leading coronavirus vaccine, which helped

Healthcare in the United States is big business: Experts believe the system could generate more than $6 trillion in annual spending by 2030. That's an opportunity for investors to find the key

Is the stock market surge of 2023 running out of steam? That seems to be the case. The S&P 500 has retreated from the lofty levels of just a couple of months ago.

But there are some stocks that

Americans might not be as coronavirus-weary as some fear. Actually, these days they might be more coronavirus-wary. On the back of early take-up data for the latest COVID-19 vaccines that came out

Pfizer (NYSE: PFE) is a company that's in the midst of a transition. The COVID-19 vaccine maker benefited from a huge revenue boost due to the pandemic. Now, however, as the government is no longer

Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX).

Ginkgo Bioworks (NYSE: DNA) is having a strong showing today. Specifically, the synthetic biology company's shares were up by 10.1% on heavy volume as of 9:57 a.m. ET Wednesday morning.

What's

UnitedHealth Group (NYSE: UNH) has seen its shares decline more than 6% so far this year. That may not seem like much of a drop, but for a company as steady as UnitedHealth, that represents a

The Food and Drug Administration (FDA) just approved the updated Omicron-adapted COVID-19 booster shots from Moderna (NASDAQ: MRNA) and the COVID-19 booster that Pfizer (NYSE: PFE) and BioNTech

Pfizer (NYSE: PFE) is a stock that everyone's familiar with, but that doesn't mean that everyone agrees you should buy it. While its promise of steady returns and a decent dividend might be

Innovation never sleeps in the healthcare sector. At the beginning of this year, there had never been a vaccine approved by the U.S. Food and Drug Administration (FDA) for the prevention of the

We all love a good bargain, whether we're shopping for food, clothing -- or stocks. And even though the stock market has gained this year -- with the S&P 500 rising in the double digits -- there

Healthcare is an evergreen frontier for investing. An endless need for better treatments and cures demands innovation and growth, which isn't a bad place to find long-term winners you can stick in a